People · Operator
Named in public records as an officer, director or promoter · active 2008–2008 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neogenix Oncology Inc | — | Biotechnology | Series C | $80.8M | $30.6M | 2008 |
Thomas Lytle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas Lytle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Gordon | 1 | 4 |
| Philip Arlen | 1 | 2 |
| J. Douglas Holladay | 1 | 2 |
| Timothy P. Shriver | 1 | 1 |
| Myron Arlen | 1 | 1 |
| Thomas K. Lytle | 1 | 1 |
| Lynn Krominga | 1 | 1 |
| Barry Gause | 1 | 1 |
| James Feldman | 1 | 1 |
| Dennis Greene | 1 | 1 |
| Rishab Gupta | 1 | 1 |
| William Ashton | 1 | 1 |
| William K. Ashton | 1 | 1 |
| Phillip Arlen | 1 | 1 |
| Rishab K. Gupta | 1 | 1 |
| David S. Moskowitz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.